Cel-Sci Corporation (CVM) News
Filter CVM News Items
CVM News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CVM News Highlights
- For CVM, its 30 day story count is now at 2.
- Over the past 14 days, the trend for CVM's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- SCI and NICE are the most mentioned tickers in articles about CVM.
Latest CVM News From Around the Web
Below are the latest news stories about CEL SCI CORP that investors may wish to consider to help them evaluate CVM as an investment opportunity.
CVM Stock Earnings: CEL-SCI Reported Results for Q4 2023CEL-SCI just reported results for the fourth quarter of 2023. |
CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate DevelopmentsVIENNA, Va., December 22, 2023--CEL-SCI reports fiscal 2023 financial results and clinical & corporate developments. |
CVM: NICE To Have Your SupportBy John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT Multikine Selected as Potential New Standard of Care CEL-SCI Corporation (NYSE:CVM) provided a pleasant surprise earlier this week highlighting an announcement by the British National Institute for Health and Care Excellence (NICE). The Institute has selected Multikineto to be evaluated as the potential new standard of care for |
UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck CancerVIENNA, Va., December 04, 2023--UK’S National Institute for Health and Care Excellence (NICE) selects Multikine as potential new standard of care for head & neck cancer. |
CEL-SCI Announces Closing of $5 Million Public Offering of Common StockVIENNA, Va., November 20, 2023--CEL-SCI announces closing of $5 million public offering of common stock. |
CEL-SCI Announces Pricing of $5 Million Offering of Common StockVIENNA, Va., November 16, 2023--CEL-SCI announces pricing of $5 million offering of common stock. |
12 Best Day Trading Stocks To BuyIn this article, we discuss the 12 best day trading stocks to buy. If you want to read about some more day trading stocks, go directly to 5 Best Day Trading Stocks To Buy. Over the past few years, the rise of a new generation of stock traders that like to engage in risky bets, […] |
CVM: Target Population Comes Into ReliefBy John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT Multikine Clinical Data CEL-SCI Corporation (NYSE:CVM) has continued to generate data and analysis related to its IT-MATTERS trial - a Phase III study evaluating Multikine in advanced primary squamous cell carcinoma of the oral cavity and soft palate. Since our previous update a month ago, CEL-SCI has continued to prepare its |
CEL-SCI Issues Letter to ShareholdersVIENNA, Va., October 30, 2023--CEL-SCI issues letter to shareholders. |
CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory ApprovalsVIENNA, Va., October 24, 2023--CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals. |